Aeolus Pharmaceuticals Inc. recently started a Phase 1 test of AEOL 10150 on healthy people as part of its efforts to determine whether it can delay the effects of acute radiation exposure in the lungs.
AEOL 10150 is being tested in the form of a fast-increased dose in healthy people. The testing will be done at a single location, and AEOL 10150 will be given as a shot, according to an announcement.
Aeolus Pharmaceuticals is creating AEOL 10150 to address the slowed outcomes of acute radiation exposure in the lungs, or Lung-ARS. The company is also seeking to use AEOL 10150 to treat idiopathic pulmonary fibrosis and together with radiation to treat solid tumors.
Aeolus Pharmaceuticals will mark the outcomes of this test in its pre-Emergency Use Authorization for Lung-ARS and help try to get it approved to use to fight idiopathic pulmonary fibrosis and for use with radiation. Aeolus will also mark the outcomes of this test to use it to treat lung damage caused by sulfur mustard gas.
Previous AEOL 10150 studies in which the treatment was given in one and many doses have shown it to be safe to and tolerated by patients.
The Biomedical Advanced Research and Development Authority is providing $118.4 million for the testing in an advanced research and development contract.
